Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Renal Cell Carcinoma | Unmet Need | Metastatic Renal Cell Carcinoma | US/EU | 2018

Login to access report north_east
Contact sales account_box

The treatment armamentarium for renal cell carcinoma mainly comprises small-molecule antiangiogenic inhibitors and immune checkpoint inhibitors. Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor Opdivo, which was approved for this indication as monotherapy in 2015 and in combination with the CTLA-4 inhibitor Yervoy in 2018, has revolutionized clinical practice. Although existing treatment options aim to improve PFS, significant need remains for well-tolerated therapies that can extend the OS and PFS of patients with advanced or metastatic renal cell carcinoma.

QUESTIONS ANSWERED

  • What are the treatment drivers that are most likely to influence a therapy’s uptake for advanced or metastatic renal cell carcinoma?
  • How do current therapies for advanced or metastatic renal cell carcinoma perform on key attributes?
  • What are the prevailing areas of unmet need and hidden opportunities in this patient population?
  • What trade-offs are surveyed medical oncologists willing to make across key clinical attributes and price when considering hypothetical new treatment options for advanced or metastatic renal cell carcinoma?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…
north_east
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
north_east
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
north_east
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east